Compound K Enhances Insulin Secretion with Beneficial Metabolic Effects in db/db Mice

Gi Cheol Han, Sung Kwon Ko, Jong Hwan Sung§ and Sung Hyun Chung*
Department of Life and Nanopharmaceutical and Department of Pharmaceutical Science, Kyung Hee University, Seoul 130-701, Korea, Department of Oriental Medical Food & Nutrition, Semyung University, Jecheon 390-711, Korea, and ILHWA Co. Ltd., Central Research Center, Guri 471-711, Korea
J. Agric. Food Chem., 2007, 55 (26), pp 10641–10648
DOI: 10.1021/jf0722598
Publication Date (Web): November 23, 2007
Copyright © 2007 American Chemical Society

Kyung Hee University.

,

Semyung University.

,
§

ILHWA Co. Ltd.

,
* To whom correspondence should be addressed. Tel: +822-961-0373 . Fax: +822-957-0384 . E-mail: suchung@khu.ac.kr.

Abstract

Compound K (CK) is a final metabolite of panaxadiol ginsenosides. Although Panax ginseng is known to have antidiabetic activity, the active ingredient is not yet fully identified. In our preliminary studies, panaxadiol ginsenosides showed insulin secretion stimulating activity. Therefore, it would be interesting to know whether and how CK has antidiabetic activity. In in vitro studies using HIT-T15 cells and primary cultured islets, CK enhanced the insulin secretion in a concentration-dependent manner. This effect, however, was completely abolished in the presence of diazoxide (K+ channel opener) or nifedipine (Ca2+ channel blocker). Insulin secretion stimulating activity of a single oral CK administration was also confirmed with an oral glucose tolerance test (OGTT) using ICR mice. From these studies, we may conclude that CK lowered the plasma glucose level by stimulating insulin secretion and this action was presumably associated with an ATP-sensitive K+ channel. In a long-term study using C57BL/KsJ db/db mice, CK treatment significantly decreased the fasting blood glucose levels in a dose-dependent fashion. OGTT revealed that CK improved glucose tolerance with increased insulin levels 30 min after the glucose challenge. Concurrently, CK treatment prevented the destruction of islets and preserved more insulin. Next, to gain insight into the extra-pancreatic molecular mechanism of CK, we performed a global gene expression profiling study in the liver and adipose tissues. According to DNA microarray analysis, CK shifted glucose metabolism from hepatic glucose production to hepatic glucose utilization in the liver and improved insulin sensitivity through enhancing plasma adiponectin levels, resulting in overexpression of genes for adipogenesis and glucose transporter in the adipose tissue. Taken together, we may suggest that CK could be developed as a therapeutic tool in type 2 diabetic patients with disability of insulin secretion and/or insulin resistance.

Tools

History

  • Published In Issue December 26, 2007
  • Article ASAPNovember 23, 2007
  • Received: July 27, 2007
    Accepted:  ,
    Revised: October 19, 2007

Recommend & Share

Related Content

Other ACS content by these authors: